Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Phase I Trial of Tazemetostat in Combination with Venetoclax in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Clinical Trial Details

This is a research study to test the safety of the investigational combination of tazemetostat and venetoclax for patients with non-Hodgkin lymphoma (NHL) whose disease has returned after having received prior treatment (relapsed), or whose disease has failed to respond to prior treatments (refractory).

This study will find the highest dose of venetoclax that can be given with tazemetostat without causing severe side effects. Both of these medications have been studied in patients with lymphoma and have been shown to be safe, however, they have not been used in combination.

All participants will receive a combination of oral 800 mg tazemetostat and oral venetoclax. The dose of venetoclax will be determined by the study team.

Participants will need to regularly come to the clinic for blood work, imaging, and to monitor any side effects. Participants may receive study drug until their cancer progresses or for up to 24 months.

Key Eligibility: 
  1. Open to adults over the age of 18
  2. Participants must have histologically confirmed, biopsy-proven diagnosis of Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
  3. Participants must have been treated with at least two prior lines of therapy for lymphoma with evidence of disease progression.

Detailed eligibility will be reviewed when you contact the study team.

Study contact by location

Upper East Side - Manhattan

Contact(s)

June Greenberg, RN
(212) 746-2651
jdg2002@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

2204024678

ClinicalTrials.gov:

NCT05618366

Status

Open to Enrollment

Age Group

Adult

Sponsor